“Those responsible are without remorse, so there must be a reckoning. Barring that reckoning, we promise you they will make us remorseful later for not holding them accountable now.” ~“Rise of the Fourth Reich: Confronting COVID Fascism with a New Nuremberg Trial, So This Never Happens Again”
Do we have to wait for two years’ worth of death and injury reports from the incoming RSV shots before we begin warning against them? Or have we learned anything from Pfizer and Moderna’s fraudulent trials on COVID?
Last week, the CDC’s Advisory Committee on Immunization Practices met to discuss the future framework of a number of vaccines. Of course, all of them were deemed safe enough to continue, although a number of shocking nuggets of data were revealed with the understanding that the public will never discover this information. According to FDA briefing documents, two people in the Pfizer RSV trial for those over 60 years old experienced the dangerous form of neuropathy known as Guillain-Barré syndrome. The rate was 1 in 9,000, which is bad enough, but we’ve seen from COVID that GBS is a fairly common reaction, and Bell’s palsy, a similar form of neuropathy, has racked up 16,755 entries in VAERS.
This is particularly concerning because in the Phase 1/2 trial for Pfizer’s RSV shot, among a younger cohort of 18- to 49-year-olds, the trial reports one death among the 164 participants in the group getting 120 micrograms (the dose now recommended for seniors). “One participant in the 120-µg RSVpreF group died within 12 months postvaccination 1 due to toxicity to various agents (quetiapine and amlodipine) that was considered not vaccine-related,” reports Pfizer. After everything we experienced with the fraud from the COVID trials, are we really to trust that a disclosed death due to toxicity was somehow confirmed not to be related to the vaccine?
GlaxoSmithKline already had to pause its RSV trial for pregnant women due to safety concerns. According to Pharma Intelligence, one death occurred in the trial, attributed to acute disseminated encephalomyelitis 22 days after vaccination, “considered by both the study investigator and FDA to potentially be related to the vaccine.” Meanwhile, GSK’s shot for elderly people appears to be right on track, even though, as Dr. Meyrl Nass reports, ACIP participants raised questions about the fact that this shot “can overstimulate the immune system, which is why it is only used for the elderly or immunocompromised.” How in the world can anything that “overstimulates” the immune system be approved for anyone of any age after everything we’ve seen with COVID and all of the problems with neuropathies and autoimmune disorders stemming from this overstimulation?
Yet despite all these concerns, and despite just having experienced a tsunami of adverse events from rushed COVID shots, the FDA and CDC are continuing to step on the gas pedal of the “vax at all costs” cultish vehicle to make Josef Mengele great again. On Tuesday, the FDA’s Vaccines and Related Biological Products Advisory Committee voted 7-4 to approve the Pfizer senior shot. Even if you trust the top-line data, the FDA has no specific data on how long protection lasts, how effective the shot is in the immunocompromised, or how it interacts with other common vaccines like the flu shot — or the COVID shots!
Interference with the flu shot was a particular concern to panel chair Hana El Sahly, a microbiology professor at Baylor College of Medicine. “I was left with the idea that there is interference,” she said. “And whether we like it or not, this vaccine is going to be given in the fall around the time of administration of influenza.”
Dr. Marie Griffin of Vanderbilt University Medical Center, another member of the committee who opposed the recommendation, raised concerns that all of the efficacy data was among healthy patients. This shot is likely going to be strongly pushed, if not mandated, on nursing home patients. Are we back to “test on the population first, worry about effects … never”?
Let’s not forget that Fauci recently conceded that RSV shots do not stop the virus and are really not ready for prime time. And as for clinical outcomes, how many healthy 65-year-olds die from RSV to begin with that it’s even possible to measure efficacy (claim to be 85 percent) on death and critical illness?
Read the rest here.
